Tiger Brokers

  • Quotes
  • Invest
  • Pricing
  • Download
  • Rewards
  • Help
  • TigerAI
  • Institution
    • Wealth and asset manager
    • Proprietary trading institutions
    • Introducing brokers
    • Third-party service provider
    • Esop
  • About
    • About us
    • Newsroom
    • Awards
  • LOGIN
  • SIGN UP
US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

21.97
+0.73003.44%
Volume:185.11K
Turnover:3.99M
Market Cap:2.49B
PE:-6.35
High:21.97
Open:21.47
Low:21.27
Close:21.24
52wk High:34.29
52wk Low:13.18
Shares:113.29M
Float Shares:101.00M
Volume Ratio:0.99
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4579
EPS(LYR):-3.3245
ROE:-65.74%
ROA:-30.16%
PB:4.41
PE(LYR):-6.61

Loading ...

OverviewCompanyNewsFilings

Viridian Therapeutics Exec Says Co Has a Lot of Pricing 'Optionality' for Elegrobart After Late-Stage Data – Conf Call

THOMSON REUTERS
·
Mar 30

Top Premarket Decliners

MT Newswires Live
·
Mar 30

Viridian Therapeutics Shares Down 33.5% Premarket After Co Reports Late‑Stage Trial Data for Its Thyroid Eye Disease Drug

THOMSON REUTERS
·
Mar 30

Viridian's thyroid eye disease drug succeeds in late‑stage trial

Reuters
·
Mar 30

Viridian announces results from elegrobart REVEAL-1 phase 3 trial

TIPRANKS
·
Mar 30

Viridian says elegrobart hits primary endpoint in Phase 3 REVEAL-1 thyroid eye disease trial

Reuters
·
Mar 30

Viridian Therapeutics Inc - Elegrobart Generally Well Tolerated With Low Rates of Hearing Impairment

THOMSON REUTERS
·
Mar 30

Viridian Therapeutics Inc - Reveal-1 Trial Meets Primary Endpoint With Statistically Significant Q4w Proptosis Responder Rate

THOMSON REUTERS
·
Mar 30

Viridian Therapeutics Announces Positive Topline Results From Elegrobart Phase 3 Reveal‑1 Clinical Trial in Active Thyroid Eye Disease

THOMSON REUTERS
·
Mar 30

Analyst Rate

Buy
Buy
100.00%
Hold
0.00%
Sell
0.00%

Corporate Actions

Financial Report Announcement
Aug 06, 2026 Pre-MKt
Financial Report Announcement
May 05, 2026 Pre-MKt
Financial Report Announcement
Feb 26, 2026 Pre-MKt
Financial Report Announcement
Nov 05, 2025 Pre-MKt
Financial Report Announcement
Aug 06, 2025 Pre-MKt

Dividend History

no data

No relevant data is available

Valuation Analysis

-6.32
Current
-5.75
Sector Average
29.89%
Historical Percentile
P/E[TTM]
+1 STD
Average
-1 STD
Current
-6.32
Maximum
-0.84
+1 STD
-3.28
Minimum
-13.35
-1 STD
-8.22
Average
-5.75

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10
     
     
     
     
Company Name:
Tiger Trade Technology Pte. Ltd.
Email Address:
dpo@itiger.com
User Agreement|Privacy Policy

Copyright © Tiger Trade Technology Pte. Ltd.

Product offerings in different jurisdictions may vary.

Information contained on this website is general in nature and does not take into account of your investment objectives, financial situation and specific needs. It should not be regarded as an offer to sell, asolicitation to buy, a recommendation or endorsement for any financial product, nor does it constitute an investment forecast, investment return commitments, investment suggestions or other practical operating opinions. Information contained on this website is for reference only and past performance should not be construed as future performance. Investment involves risks. Before you make an investment decision, you should carefully judge and screen whether the information contained on this website is appropriate for your needs, goals and circumstances.

We strive but cannot guarantee the accuracy, completeness, reliability and timeliness of all information on this website, and we are not responsible for any losses caused by the use of or reliance on relevant information.

The products and services offered on the website are subject to applicable laws, regulations and relevant agreements. Please carefully read and agree to the agreements before using our products and services.